Handelsbanken Fonder Ab Morphic Holding, Inc. Transaction History

Handelsbanken Fonder Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$26.12 - $34.07 $26,120 - $34,070	1,000 Added 8.7%	12,500 $426,000
Q1 2024 May 13, 2024	BUY	$26.64 - $40.31 $55,944 - $84,651	2,100 Added 22.34%	11,500 $405,000
Q4 2023 Feb 01, 2024	BUY	$19.95 - $31.0 $187,530 - $291,400	9,400 New	9,400 $271,000
Q2 2023 Aug 02, 2023	BUY	$34.33 - $62.11 $181,949 - $329,183	5,300 New	5,300 $304,000
Q1 2022 May 11, 2022	SELL	$36.25 - $52.02 $170,375 - $244,494	-4,700 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$43.27 - $65.72 $203,369 - $308,884	4,700 New	4,700 $223,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.